GSK and Vir Biotechnology announce joint procurement agreement with European Commission for COVID-19 treatment, sotrovimab

The companies will supply up to 220,000 doses of this investigational single dose SARS-CoV-2 monoclonal antibody for treatment of adults & adolescents (aged ≥12 years; ≥40 kg) with COVID-19 who do not require oxygen and who are at risk of progressing to severe COVID-19.

SPS commentary:

This action follows the positive scientific opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The documentation to support the forthcoming marketing authorization application for sotrovimab is under rolling regulatory review with the EMA.

Biospace Inc.